Research And Development Tenders

Open House Discount Contracts 2024-05

Open Framework Agreement on Drug Discounts in Accordance with Section 130A Paragraph 8 Sgb V with the Possibility of Joining at any Time, So-Called Approval Model 2024-03

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for Various Active Ingredients/Combinations with the Possibility of Conclusion at any Time as Part of...

Open Framework Agreement on Drug Discounts in Accordance with Section 130A Paragraph 8 Sentence 1 Sgb V with the Possibility of Joining at any Time, So-Called Approval Model 2024-03

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Follitropin Alfa (Atc Code: G03ga05).

Drug Contracts with an Option to Join

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Fampridine (Atc Code: N07xx07).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Palonosetron (Atc Code: A04aa05).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Botulimum Toxin Type a (Atc Code: M03ax21).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Tolvaptan (Atc Code: C03xa01 and G04bx21).